Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255841 | 0.82 | SLC6A4 (0.42) | KCNH2SRD5A1HRH3 | |
| SCHEMBL18252818 | 0.82 | HTR2B (0.42) | KCNH2HTR2BCHRM2HTR1ADRD3 | |
| SCHEMBL18252817 | 0.81 | KCNH2 (0.43) | KCNH2HTR2BCHRM2HTR1ADRD3 | |
| SCHEMBL18252814 | 0.81 | KCNH2 (0.43) | KCNH2HTR2BCHRM2HTR1ADRD3 | |
| SCHEMBL18252841 | 0.81 | KCNH2 (0.43) | KCNH2HTR2BCHRM2HTR1ADRD3 | |
| SCHEMBL23938306 | 0.81 | PNMT (0.37) | KCNH2HTR2BSRD5A1DPP7FFAR1 | |
| SCHEMBL20013725 | 0.79 | KCNH2 (0.37) | KCNH2TMEM97SIGMAR1SRD5A1DPP7 | |
| SCHEMBL13938028 | 0.74 | TMEM97 (0.54) | KCNH2HTR2BCHRM2HTR1ADRD3 | |
| SCHEMBL18254951 | 0.70 | CHRNB2 (0.45) | HTR2BHTR2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL17993834 | 0.69 | TMEM97 (0.47) | KCNH2HTR2BCHRM2HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CHEMOCENTRYX, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190269664-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-11 | — | — | US | disclosed |
| US-20190134049-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | KCNH2 4737/4885HTR2B 1799/4885CHRM2 1980/4885 |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | KCNH2 3915/4885HTR2B 1773/4885CHRM2 620/4885 |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CCR2, CXCR2, CCRL2 | KCNH2 3915/4885HTR2B 1773/4885CHRM2 620/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | KCNH2 4753/4885HTR2B 476/4885CHRM2 456/4885 |
| US-20190269664-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | KCNH2 3829/4885HTR2B 1807/4885CHRM2 596/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | KCNH2 4753/4885HTR2B 476/4885CHRM2 456/4885 |
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | KCNH2 4737/4885HTR2B 1799/4885CHRM2 1980/4885 |
| US-20190134049-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | KCNH2 4737/4885HTR2B 1799/4885CHRM2 1980/4885 |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CCR2, PDCD1LG2, CD274 | KCNH2 4737/4885HTR2B 1799/4885CHRM2 1980/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | KCNH2 4506/4885HTR2B 769/4885CHRM2 595/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | KCNH2 4737/4885HTR2B 1799/4885CHRM2 1980/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | KCNH2 4747/4885HTR2B 597/4885CHRM2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.